VELRAYDY
Live / Allowed — First extension granted (statement of use) (as of 17 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 25 Jul 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99303003
- Mark type
- Word mark
- Filed
- 25 Jul 2025
- Published for opposition
- 13 Jan 2026
- Attorney of record
- Alexandra Kochian
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of somatostatin-expressing neuroendocrine tumors; Pharmaceutical preparations for the treatment and prevention of oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Radiopharmaceutical preparations for the treatment of oncological, gastrointestinal, and hepatological diseases and disorders
Owner
- Genzyme Corporation, Cambridge, MA, US
- Genzyme Corporation, Cambridge, MA, US
Prosecution history
- 18 Aug 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Aug 2026 — SOU EXTENSION 1 GRANTED
- 17 Aug 2026 — SOU EXTENSION 1 FILED
- 17 Aug 2026 — SOU TEAS EXTENSION RECEIVED
- 14 Jul 2026 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 10 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Jan 2026 — PUBLISHED FOR OPPOSITION
- 07 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Dec 2025 — ASSIGNED TO EXAMINER
- 20 Aug 2025 — PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
- 18 Aug 2025 — ASSIGNED TO LIE
- 06 Aug 2025 — TEAS VOLUNTARY AMENDMENT RECEIVED
- 25 Jul 2025 — APPLICATION FILING RECEIPT MAILED